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Aim To investigate whether bradykinin-independent anti-
oxidative effects of angiotensin-converting enzyme inhibi-
tors (ACEIs)  exist in acute hyperglycemia.
Methods Male Wistar rats were divided into the normo-
glycemic group (n = 40) and the hyperglycemic group 
(n = 40). Hyperglycemia was induced by a single intrap-
eritoneal injection of streptozotocin (STZ, 65 mg/kg body 
weight), dissolved in 0.1 mol/L citrate buffer (pH 4.5), 72 
hours before sacrifice. The normoglycemic group received 
the same volume of citrate buffer. Each group was divided 
into five subgroups (n = 8): control group, captopril group, 
captopril + bradykinin B1 and B2 receptor antagonists 
group, enalapril group, and enalapril + bradykinin B1 and 
B2 receptor antagonists group. Captopril, enalapril, B1 and 
B2 receptor antagonists, or 0.15 mol/L NaCl were given at 
2 and 1 hour before sacrifice. Oxidative status was deter-
mined by measuring the concentration of malondialde-
hyde and H2O2, and the activity of superoxide dismutase 
(SOD), catalase (CAT), and glutathione peroxidase (GPx).
Results In STZ-induced hyperglycemic rats ACEIs signifi-
cantly reduced H2O2 and MDA concentration, while they 
significantly enhanced SOD and GPx activity. The hypergly-
cemic group treated simultaneously with ACEIs and brady-
kinin B1 and B2 receptor antagonists showed a significant 
decrease in H2O2 concentration compared to the control 
hyperglycemic group.
Conclusion These results suggest the existence of addi-
tional antioxidative effect of ACEIs in hyperglycemic condi-
tions, which is not related to the bradykinin mediation and 
the structure of the drug molecule.
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Hyperglycemia is a predominant pathogenic factor in mi-
cro- and macrovascular complications in diabetes mellitus 
(DM). However, there is evidence that acute glucose fluc-
tuations have a greater impact on oxidative tissue damage 
in DM than sustained hyperglycemia (1). Hyperglycemia 
induces mitochondrial superoxide overproduction, lead-
ing to the activation of the consecutive sources of reac-
tive oxygen, such as nicotinamide adenine dinucleotide 
phosphate oxidases (NADPH oxidases), uncoupled en-
dothelial nitric oxide synthase (eNOS), protein kinase C 
isoforms, polyol and hexosamine pathways, as well as the 
increased formation of advanced glycation end products 
(AGEs) and stress-activated proteins including nuclear 
factor-κB (NF-κB), p38 kinase activated by mitogen (p38 
MAPK), NH2-terminal Jun kinases/stress-activated protein 
kinases (JNK/SAPK), and Janus kinase/signal transducer 
and activator of transcription (JAK/STAT). In addition, hy-
perglycemia impairs the endogenous antioxidant defense 
system (2-4). This imbalance between radical-generating 
and radical-scavenging processes is an important factor in 
the mechanism of diabetic tissue damage. Considerable 
experimental and clinical evidence indicates a role of the 
renin-angiotensin system (RAS) in the pathogenesis of DM 
(5,6). It has been shown in both animal models and hu-
mans that DM is characterized by an elevated activity of 
angiotensin converting enzyme (ACE) (7,8). ACE converts 
angiotensin I (ANG-I) to angiotensin II (ANG-II), a potential-
ly prooxidative agent, and simultaneously inactivates bra-
dykinin, which is thought to have antioxidative properties. 
Accordingly, it can be assumed that ACE inhibition may 
play a certain role in the prevention of oxidative stress and 
DM development.
ACEIs are widely used in the treatment of cardiovascular 
diseases, especially hypertension, as well as atherosclero-
sis, myocardial infarction, and congestive heart failure. Ad-
ditionally, as shown by several randomized trials, ACEIs and 
ANG-II receptor blockers (ARBs) are powerful agents mini-
mizing the risk of DM (6,9). The majority of the beneficial ef-
fects of ACEIs result from the decrease in ANG-II concentra-
tion, increase in bradykinin bioavailability, and activation 
of intracellular bradykinin-dependent mechanisms (10,11). 
Bradykinin exerts physiologic effects through two types 
of G-protein-coupled receptors: type 2 (B2Rs) and type 1 
(B1Rs). However, its biological action, including antioxida-
tive activity, is mainly mediated through B2Rs. B1Rs are 
highly expressed or synthesized de novo under the influ-
ence of inflammatory factors, growth promoters, as well 
as hyperglycemia (12,13). Studies on a rat model of in-
sulin resistance have shown that the B1Rs activation 
leads to the increased production of superoxide through 
NADPH oxidase (14). ACEIs can enhance both B1R and B2R 
signaling, acting as direct allosteric agonists of B1Rs, and as 
indirect allosteric enhancers of kinin B2Rs, via inactivation 
of ACE (15). Antioxidant effects of ACEIs are well known 
and widely accepted (10,16-18). Most studies suggest that 
this is the result of bradykinin action, however, ACEIs may 
also activate B1Rs and, thereby, enhance O2•− production 
(19,20). Thus, the overall impact of ACEIs on oxidative pro-
cesses has not been completely clarified yet. In this con-
text, the aim of the study was to investigate whether bra-
dykinin-independent antioxidative effects of ACEIs exist in 
streptozotocin (STZ)-induced acute hyperglycemia. Con-
sidering that both types of kinin receptors are involved in 
the regulation of the redox state, and that ACEIs affect their 
activity, we used B1 and B2 receptor antagonists to elimi-
nate this pathway of ACEIs action.
MEtHODs
Animals
All experimental and animal care procedures were con-
ducted in accordance with the European Convention for 
the Protection of Vertebrate Animals Used for Experimental 
and Other Scientific Purposes (ETS 123/1986 and Appen-
dix A/2006: Guidelines for accommodation and care of ani-
mals) and with the directive 2010/63/UE of the European 
Parliament and Council, as well as were approved by the Lo-
cal Ethics Committee for Animal Experimentation in Poznań 
(Protocol No. 80/2013). The studies were performed on syn-
genic, healthy, adult, male Wistar rats with an average body 
weight of 250 ± 30 g. The animals were maintained on a 
12-hour light-dark cycle in a humidity- (50 ± 5%) and tem-
perature- (21 ± 1°C) controlled room, with a ventilation rate 
of 12 air changes per hour, and had free access to water 
and food (standard laboratory diet, Labofeed B, Feed Fac-
tory “Morawski”, Żurawia, Poland). All experiments were car-
ried out at the same time in the morning. After two weeks 
of acclimatization and observation, the animals were divid-
ed into two experimental groups of 40 animals each: one 
group of rats with normoglycemia receiving 1.0 mL of 0.1 
mol/L fresh cold citrate buffer (pH 4.5), intraperitoneally 72 
h before sacrifice and the group of rats with hyperglycemia 
induced by an intraperitoneal injection of STZ (Sigma-Al-
drich, Inc., St. Louis, MO, USA), 65 mg/kg body weight (21), 
into 12 h-fasted rats, 72 h before sacrifice. STZ was dissolved 
in 1.0 mL of 0.1 mol/L citrate buffer (pH 4.5). Hyperglycemia 
was verified by measuring fasting plasma glucose using 
Liquick Cor-GLUCOSE kit (Cormay, S.A., Lublin, Poland), and 
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diagnosed by glucose concentration >15 mmol/L. Plasma 
insulin concentration was measured by radioimmunoassay, 
using Insulin RIA kit (Linco Research, Inc., St. Charles, MO, 
USA). Each group was divided into five subgroups. Con-
trol subgroup (Control, n = 8) received 1.0 mL of 0.15 mol/L 
NaCl, intraperitoneally, 2 hours and 1 hour before sacrifice. 
Captopril subgroup (CAP, n = 8) received 1.0 mL of 0.15 
mol/L NaCl, intraperitoneally, 2 hours, and captopril (Sig-
ma-Aldrich, Inc., St. Louis, MO, USA), 3 mg/kg body weight 
(22), intraperitoneally, 1 hour before sacrifice. Captopril plus 
antagonists subgroup (CAP+ANT, n = 8) received HOE-140 
(D-Arg-[Hyp3,Thi5,Dtic7-Oic8]-bradykinin), a B2Rs antago-
nist (Sigma-Aldrich, Inc., St. Louis, MO, USA), 300 μg/kg 
body weight (23), subcutaneously, and desArg9[Leu8]-bra-
dykinin, a B1Rs antagonist (Sigma-Aldrich, Inc.), 300 μg/kg 
body weight (24), subcutaneously, 2 hours, and captopril, 
intraperitoneally, 3 mg/kg body weight 1 hour before sacri-
fice. Enalapril subgroup (ENP, n = 8) received 1.0 mL of 0.15 
mol/L NaCl, intraperitoneally, 2 hours, and enalapril (Sigma-
Aldrich, Inc.), 1 mg/kg body weight (25), intraperitoneally, 1 
hour before sacrifice. Enalapril plus antagonists subgroup 
(ENP+ANT, n = 8) received HOE-140 and desArg9[Leu8]-bra-
dykinin 2 hours, and enalapril 1 hour before sacrifice. Drug 
doses and the administration route were the same as re-
spectively in the CAP+ANT and ENP subgroup. Captopril, 
enalapril, and B1 and B2 receptor antagonists were dis-
solved in 0.15 mol/L NaCl. Rats were anesthetized with a 
single intraperitoneal injection of ketamine hydrochloride 
(Bioketan, Vetoquinol Biowet, Sp. z o.o., Gorzów Wlkp., Po-
land), 100 mg/kg body weight and xylazine hydrochloride 
(Xylapan, Vetoquinol Biowet, Sp. z o.o., Gorzów Wlkp., Po-
land), 10 mg/kg body weight. After sampling the rats were 
killed by exsanguination (Figure 1).
tissue sampling and analyses
Blood samples were taken from the anaesthetized rats by 
the puncture of the right ventricle, collected in heparin-
ized tubes, and prepared as described by the kits’ manu-
facturers and using Frew procedure (26).
The concentration of plasma malondialdehyde was deter-
mined using assay kit BIOXYTECH® MDA-586 (OXIS Interna-
tional, Inc., Beverly Hills, CA, USA). The method is based on 
the reaction of N-methyl-2-phenylindole (NMPI) with MDA 
at 45°C in the presence of HCl. One molecule of MDA re-
acts with two molecules of NMPI to create a stable chro-
mophore form with a maximum absorbance at 586 nm. 
The absorbance was measured spectrophotometrically 
(Beckman Coulter, Inc., Brea, CA, USA) at 586 nm. MDA con-
centration was expressed as µmol/L.
The concentration of plasma hydrogen peroxide (H2O2) 
was determined spectrophotometrically using the Frew 
procedure (21). The reagent solution (100 mL) contained 
0.234 g of phenol, 0.1 g of 4-aminoantipyrine, 1.0 mL of 
0.1 mol/L phosphate buffer (pH 6.9), about 2 × 10−8 horse-
radish peroxidase (HRP), and about 2.5 µmol/L H2O2. H2O2 
coupled with 4-aminoantipyrine, and phenol, in the pres-
ence of peroxidase, to yield a chromogen with maximum 
absorbance at 505 nm. H2O2 concentration was expressed 
as mmol H2O2/mL.
Antioxidative enzymes activities were measured in the 
erythrocyte fractions. SOD activity was determined us-
ing assay kit BIOXYTECH® SOD-525 (OXIS Internation-
al, Inc.). The method is based on the SOD-catalyzed 
FiGurE 1. Experimental protocol. streptozotocin (stZ), captopril (CAP), enalapril (ENP), bradykinin receptor antagonists (ANt).
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increase of autooxidation of 5,6,6a, 11b-tetrahydro-3,9,10-
trihydroxybenzo[c]-fluorene to a chromophore form with 
maximum absorbance at 525 nm. The absorbance chang-
es were determined spectrophotometrically at 525 nm at 
10-second intervals for one minute. SOD activity was ex-
pressed as U/mg Hb.
CAT activity was determined using assay kit BIOXYTECH® 
Catalase-520 (OXIS International, Inc.). The method is a 
two-step procedure based on the assumption that the 
rate of dismutation of H2O2 to water, and molecular oxy-
gen is proportional to the concentration of CAT. In the first 
step the sample containing CAT was subjected to one-
minute incubation in a known concentration of H2O2. Af-
ter incubation the reaction was quenched with sodium az-
ide. In the second step the amount of H2O2 remaining in 
the sample was determined by the coupling reaction of 
H2O2 with 4-aminophenazone (4-aminoantipyrene, AAP), 
and 3,5-dichloro-2-hydroksybenzenesulfonic acid (DHBS) 
in the presence of HRP, acting as a catalyst. The absorbance 
of the resulting colored product, quinoneimine, was mea-
sured spectrphotometrically at 520 nm. CAT activity was 
expressed as U/mg Hb.
GPx activity was measured using assay kit RANSEL RS 505 
(Randox, Crumlin, UK). In this method GPx catalyzes the 
oxidation of glutathione by cumene hydroperoxide. In the 
presence of glutathione reductase and NADPH the oxi-
dized glutathione is converted to the reduced form with a 
concominant oxidation of NADPH to NADP+. The produc-
tion of NADP+ was measured spectrophotometrically at 340 
nm. GPx activity was expressed as U/g Hb.
statistical analysis
Data are expressed as a mean ± standard deviation (SD) 
obtained from n = 8 rats. The normality of the data distri-
bution was tested using the Shapiro-Wilk test (STATISTICA 
12.5., StatSoft Polska, Kraków, Poland, P > 0.050 as normal). 
Statistical significance was determined by using the one-
way ANOVA followed by the Tukey post-hoc analysis (STA-
TISTICA 12.5.) or the Welch ANOVA and the Games-How-
ell post-hoc procedure for multiple comparisons (PQStat 
1.6.2., PQStat Software, Poznań, Poland). Differences were 
considered to be statistically significant at P < 0.050.
rEsults
STZ administration increased plasma glucose (P < 0.001) 
and decreased plasma insulin (P < 0.001) in comparison to 
the normoglycemic group (Table 1). Captopril and enal-
april significantly decreased glucose concentration in hy-
perglycemic rats (P < 0.001) and significantly increased 
insulin concentration (P = 0.002) in comparison to the con-
trol hyperglycemic subgroup (Table 1, Figure 2). Captopril 
and enalapril also significantly decreased plasma glucose 
(P < 0.001 and P = 0.044, respectively) in hyperglycemic 
rats pre-treated with HOE-140 and desArg9[Leu8]-brady-
kinin in comparison to the control hyperglycemic sub-
group (Table 1, Figure 2). H2O2 and MDA concentration in 
plasma of hyperglycemic rats was significantly increased 
(P < 0.001) in comparison to the normoglycemic group (Ta-
ble 2). Captopril and enalapril in hyperglycemic rats signifi-
cantly decreased H2O2 and MDA concentration (P < 0.001) 
in comparison to the control hyperglycemic subgroup 
tAblE 1. Glucose (mmol/l) and insulin (mu/l) concentration in plasma of normoglycemic and hyperglycemic rats after captopril 
(CAP), enalapril (ENP), and bradykinin receptor antagonists (ANt) administration*†‡
Control CAP CAP+ANt ENP ENP+ANt
Glucose (mmol/l)
Normoglycemia  5.93 ± 0.22  5.81 ± 0.31  6.00 ± 0.23  5.84 ± 0.41  5.92 ± 0.34
P†  0.234  0.137  0.737  0.125  0.094
Hyperglycemia 20.24 ± 1.08 12.42 ± 0.93§ 18.24 ± 0.61§II 11.93 ± 0.71§ 18.98 ± 0.87§¶
P†  0.098  0.164  0.760  0.298  0.863
insulin (mu/l)
Normoglycemia 46.94 ± 1.24 46.63 ± 2.01 45.93 ± 1.69 46.49 ± 1.81 46.83 ± 1.48
P†  0.209  0.479  0.211  0.244  0.283
Hyperglycemia  2.53 ± 0.58  3.82 ± 0.23§  2.64 ± 0.31II  3.71 ± 0.21§  2.64 ± 0.21¶
P†  0.423  0.320  0.461  0.375  0.172
*Data are expressed as a mean ± standard deviation, n = 8 animals per group.
†shapiro-Wilk test P values.
‡All results were statistically significant in comparison to the normoglycemic group (P < 0.001).
§P < 0.001 (ENP+ANt, P = 0.044) vs hyperglycemic control.
iiP < 0.001 vs CAP.
¶P < 0.001 vs ENP.
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(Table 2, Figure 3 A, B). In the presence of HOE-140 and 
desArg9[Leu8]-bradykinin, both captopril and enalapril sig-
nificantly decreased H2O2 concentration in rats with hy-
perglycemia in comparison to the control hyperglycemic 
subgroup (P = 0.002 and P = 0.034, respectively), but only 
captopril significantly reduced MDA concentration in rats 
treated with bradykinin receptor antagonists (P < 0.001) 
(Table 2, Figure 3 A, B). The activity of SOD, CAT, and GPx 
in erythrocytes of hyperglycemic rats was significantly de-
creased (P < 0.001) in comparison to the normoglycemic 
group (Table 3). In hyperglycemic rats treated with cap-
topril and enalapril, SOD (P = 0.006), CAT (only captopril, 
P < 0.001), and GPx (P < 0.001) were significantly increased 
in comparison to the control hyperglycemic subgroup (Ta-
ble 3). Captopril in hyperglycemic rats receiving B1 and B2 
receptor antagonists, desArg9[Leu8]-bradykinin, and HOE-
140, significantly increased SOD (P = 0.037) in comparison 
to the control hyperglycemic subgroup (Table 3, Figure 4).
tAblE 2. Hydrogen peroxide (H2O2, mmol/ml) and malondialdehyde (MDA, µmol/l) concentration in plasma of normoglycemic and 
hyperglycemic rats after captopril (CAP), enalapril (ENP), and bradykinin receptor antagonists (ANt) administration*†‡
Control CAP CAP+ANt ENP ENP+ANt
H2O2 (mmol/ml)
Normoglycemia 2.10 ± 0.18 1.69 ± 0.09 1.92 ± 0.10 1.81 ± 0.29 1.90 ± 0.46
P† 0.629 0.155 0.408 0.293 0.407
Hyperglycemia 5.74 ± 0.36 3.62 ± 0.17§ 4.97 ± 0.26§II 4.09 ± 0.14§II 5.26 ± 0.09§¶
P† 0.251 0.150 0.121 0.195 0.176
MDA (µmol/l)
Normoglycemia 3.77 ± 0.31 1.84 ± 0.21§ 3.62 ± 0.51II 3.63 ± 0.37II 4.04 ± 0.14
P† 0.176 0.159 0.221 0.097 0.095
Hyperglycemia 5.14 ± 0.17 2.76 ± 0.08§ 4.62 ± 0.16§II 3.14 ± 0.26§II 4.94 ± 0.09¶**
P† 0.708 0.401 0.113 0.366 0.349
*Data are expressed as a mean ± standard deviation (sD), n = 8 animals per group.
†shapiro-Wilk test P value.
‡All results were statistically significant in comparison to the normoglycemic group (P < 0.001).
§P = 0.002 (ENP+ANt, P = 0.034) vs respectively normoglycemic or hyperglycemic control.
iiP < 0.001 vs CAP.
¶P < 0.001 vs ENP.
**P < 0.005 vs CAP+ANt.
FiGurE 3. Oxidative stress markers concentration in plasma of hyperglycemic rats after captopril (CAP), enalapril (ENP), and bradyki-
nin receptor antagonists (ANt) administration. (A): hydrogen peroxide (H2O2, mmol/ml); (B): malondialdehyde (MDA, µmol/l). Mean 
± sD, n = 8 per group.
FiGurE 2. Glucose concentration (mmol/l) in plasma of 
hyperglycemic rats after captopril (CAP), enalapril (ENP), and 
bradykinin receptor antagonists (ANt) administration. Mean ± 
sD, n = 8 per group.
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DisCussiON
We observed that treatment with captopril or enalapril 
together with bradykinin receptor antagonists decreased 
the level of oxidative stress markers (H2O2 and MDA) and 
increased antioxidative activity in hyperglycemic rats. This 
may suggest that antioxidative properties of ACEIs under 
hyperglycemic conditions may be independent of brady-
kinin activity. Presumably, this effect is associated not only 
with the regulation of RAS, but with an influence indepen-
dent of it. The main mechanism by which ACEIs prevent 
the development of oxidative stress in hyperglycemic con-
ditions is associated with the activation of bradykinin-ni-
tric oxide-prostacyclin system. ACE inhibition increases the 
production of bradykinin, which stimulates release of vaso-
dilating substances, such as nitric oxide (NO) and prostacy-
clin (27). An improvement of blood flow increases oxygen 
supply, oxygen consumption, insulin secretion, insulin, and 
glucose delivery to the insulin-sensitive tissues, and facili-
tates insulin signaling at the cellular level. This, in turn, re-
duces serum glucose and ROS production (28,29).
Several studies have demonstrated that the beneficial ef-
fects of ACEIs in diabetic patients are attenuated by B2Rs 
antagonists, suggesting that the protective effects of ACEIs 
are mediated by bradykinin and B2Rs signaling (19,20,30,31). 
On the other hand, activation of kinin B1Rs enhances O2•− 
production, while prolonged blockade or even lack of B1Rs 
reduces oxidative stress, metabolic complications, and car-
diovascular abnormalities in hyperglycemic animals (14,32). 
This suggests that both types of kinin receptors may be in-
volved in the regulation of redox state in experimental DM. 
Recent studies indicate that ACEIs directly, as allosteric ago-
nists, or indirectly, via inactivation of ACE, affect B1R and B2R 
tAblE 3. superoxide dismutase (sOD, u/mg Hb), catalase (CAt, u/mg Hb), and glutathione peroxidase (GPx, u/g Hb) activity in eryth-
rocytes of normoglycemic and hyperglycemic rats after captopril (CAP), enalapril (ENP), and bradykinin receptor antagonists (ANt) 
administration*†‡
Control CAP CAP+ANt ENP ENP+ANt
sOD (u/mg Hb)
Normoglycemia   1.36 ± 0.07   1.34 ± 0.08   1.38 ± 0.08   1.36 ± 0.05   1.38 ± 0.07
P†   0.100   0.397   0.203   0.153   0.109
Hyperglycemia   0.74 ± 0.06   0.93 ± 0.06§   0.82 ± 0.03§II   0.85 ± 0.04§II   0.79 ± 0.01¶**
P†   0.085   0.096   0.234   0.358   0.353
CAt (u/mg Hb)
Normoglycemia 108.62 ± 4.42 106.14 ± 2.47 107.59 ± 5.17 107.11 ± 4.58 108.61 ± 3.40
P†   0.139   0.530   0.198   0.079   0.107
Hyperglycemia  90.82 ± 5.80 101.73 ± 4.70§  95.11 ± 4.80  97.36 ± 6.09  92.14 ± 3.10
P†   0.203   0.075   0.324   0.069   0.342
GPx (u/g Hb)
Normoglycemia 240.12 ± 19.18 244.49 ± 20.51 232.18 ± 19.67 242.11 ± 18.53 236.18 ± 18.41
P†   0.103   0.143   0.146   0.311   0.677
Hyperglycemia 162.11 ± 11.78 214.33 ± 15.13§ 176.55 ± 13.21II 200.37 ± 10.36§ 163.92 ± 10.02¶
P†   0.082   0.088   0.287   0.114   0.274
*Data are expressed as a mean ± standard deviation (sD), n = 8 animals per group.
† shapiro-Wilk test P value.
‡All results were statistically significant in comparison to the normoglycemic group (P < 0.001; CAt/CAP, P = 0.034).
§P < 0.001 (sOD/CAP+ANt, P = 0.037; sOD/ENP, P = 0.006) vs hyperglycemic control.
iiP < 0.001 (sOD/ENP, P = 0.037) vs CAP.
¶P = 0.006 vs ENP.
**P = 0.020 vs CAP+ANt.
FiGurE 4. superoxide dismutase activity (sOD, u/mg Hb) 
in erythrocytes of hyperglycemic rats after captopril (CAP), 
enalapril (ENP), and bradykinin receptor antagonists (ANt) 
administration. Mean ± sD, n = 8 per group.
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signaling and regulate oxidant/antioxidant status (15,33). 
Our results showed that in the presence of B1R and B2R an-
tagonists, ACEIs still decrease oxidative stress markers in the 
hyperglycemic rats. Taken together, the reduction of the an-
tioxidant ACEIs activity caused by B2Rs antagonists may be 
due to the limited action of bradykinin, however, it cannot 
be ruled out that ACEIs directly enhance antioxidative ac-
tivity and that both mechanisms (bradykinin-mediated and 
bradykinin-independent) play a role. Tasdemir et al (34) re-
ported reduced necrosis/total heart zone ratio in rats with 
myocardial infraction after captopril administration, and a 
non-significant decrease of this ratio in captopril+B2R an-
tagonist group. They concluded that non-significant de-
crease in the protective effects of captopril by B2R blocker 
indicates the existence of the routes independent of bra-
dykinin action. This route may be possibly associated with 
the activation of non-classic RAS axis and regulation of the 
prooxidative enzymes activity. It is known that RAS consists 
of two separate but reciprocally controlled axes: the classic 
ACE/ANG-II/AT1 axis, responsible for the vasoconstricting/
proliferative effects, and ACE2/ANG- (1-7)/Mas axis, which 
counter-regulates ACE activity by reducing ANG-II bioavail-
ability and simultaneously increases the formation of a vaso-
protective/antiproliferative peptide, ANG- (1-7). ACE2 is an 
endogenous regulator of RAS, which maintains the balance 
between these two axes (35). ACE2 could also be involved in 
the regulation of oxidative stress, since ACE2 knockout mice 
demonstrate elevated concentration of oxidative stress 
markers (36,37). ACEIs inhibit ACE activity but do not attenu-
ate or even increase ACE2 activity (38,39), which, in turn, in-
creases ANG- (1-7) concentration (40-44). Existing reports in-
dicate a protective effect of ANG- (1-7) in the suppression of 
oxidative stress regulated by NADPH oxidase, which is con-
sidered to be a major source of ROS in the diabetic environ-
ment (45,46). Moreover, ACEIs are also remarkably effective 
in the recoupling of eNOS. It should be noted that the un-
coupled form of this enzyme is an important source of su-
peroxide anions under pathological conditions (47-51).
It is well known that excessive glucose levels can contribute 
to the development of oxidative stress (2-4). ACEIs improve 
insulin sensitivity and glucose metabolism, and reduce 
plasma glucose both under experimental conditions and in 
patients with DM (28). Probably this effect is mostly depen-
dent on bradykinin, since it can be considerably blocked by 
bradykinin receptor antagonists (52). Our findings provide 
yet another possible mechanism. As we observed, both 
captopril and enalapril can reduce glucose concentration 
in rats treated with B1Rs and B2Rs antagonists, which indi-
cates bradykinin independent pathway. As we mentioned 
before, ACEIs increase ANG- (1-7) level (40,43). ANG- (1-7) 
stimulates adiponectin release, thereby improving insulin 
sensitivity and glucose utilization in the peripheral tissues 
(42,53). Moreover, ANG- (1-7) is able to modulate insulin 
signaling pathway through the activation of IRS-1, JAK2, 
and Akt kinase in the main target tissues for insulin (54,55). 
Also, ACEIs can probably regulate glucose level by affect-
ing the production and the activity of glucose transporters 
(42,56,57). To summarize, ACEIs, by intensifying glucose up-
take and reducing plasma glucose, may play a protective, 
antioxidative role in hyperglycemic subjects.
We also noted that captopril, in contrast to enalapril, re-
duced MDA concentration in the presence of B1Rs and 
B2Rs antagonists, which may indicate its stronger anti-
oxidant properties. Captopril is well known to have a free 
radical scavenging property, as well as reducing potency 
in various pathological conditions associated with oxida-
tive stress. The beneficial antioxidant properties of cap-
topril could probably be related to the presence of the 
unblocked sulphydryl group in the drug molecule (58). 
Sulfhydryl group as a metal chelator, radical quencher, 
and component of the thiol/disulfide redox buffer has 
been recognized as a potential free radical scavenging 
factor (59). Interestingly, in the organism only a part of 
captopril binds with ACE, whereas the rest exists in an ad-
sorbed form or as disulfides formed by the reaction with 
endogenous sulphydryl-containing compounds, such as 
glutathione or plasma proteins. Disulfides are considered 
as a drug depot, thus captopril may function as a recy-
clable antioxidant (60). In the interpretation of our results, 
a few limitations should be considered. First, STZ-induced 
experimental DM is an insulin-dependent diabetes (type 
1), therefore it may not be an appropriate model to eval-
uate the role of ACEIs and B1Rs and B2Rs antagonists in 
diabetes type 2. Second, we limited our study to acute hy-
perglycemia and a single dose of ACEIs. It should be not-
ed, however, that acute ACE inhibition reduces the ANG-
II concentration, but prolonged ACEIs treatment leads to 
ACE up-regulation and increases the ANG-II/ANG-I ratio 
(61). ANG-II is a potentially prooxidative agent (62), and 
may change the oxidant/antioxidant status, thus, chron-
ic ACEIs therapy may have a different effect on oxidative 
stress than short-term use of these drugs.
In conclusion, ACEIs are able to reduce oxidative stress in-
tensity in hyperglycemic conditions. Bradykinin appears 
to be the main factor mediating antioxidative properties 
of ACEIs, although our results suggest the existence of 
additional antioxidative effect of ACEIs in hypergly-
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cemic conditions, which is not related to the bradykinin 
mediation and the structure of the drug molecule. Further 
studies are necessary to investigate the detailed mecha-
nisms of ACEIs action.
Acknowledgments We thank Professor Paweł Maćkowiak for technical as-
sistance in the implementation of the experiment.
Funding This study was supported by a research grant (No. 502-0101125184-
04401) from Poznan University of Medical Sciences.
Ethical approval was obtained from the Local Ethics Committee for Animal 
Experimentation in Poznań.
Declaration of authorship KM contributed to the conception and study de-
sign, participated in data analysis and interpretation, wrote the manuscript, 
JK performed experimental research and biochemical analysis, participated 
in the interpretation of the results and writing technical part of the man-
uscript, JK supervised study conception, participated in study design and 
data interpretation, HK supervised study conception, participated in study 
design and data interpretation, reviewed the manuscript, EPO performed 
experimental research and biochemical analysis, participated in data inter-
pretation, wrote technical part of the manuscript, MGD participated in data 
analysis and interpretation, reviewed, drafted, and revised the manuscript,
Competing interests All authors have completed the Unified Competing 
Interest form at www.icmje.org/coi_disclosure.pdf (available on request 
from the corresponding author) and declare: no support from any organi-
zation for the submitted work; no financial relationships with any organiza-
tions that might have an interest in the submitted work in the previous 3 
years; no other relationships or activities that could appear to have influ-
enced the submitted work.
references
1 Monnier l, Mas E, Ginet C, Michel F, Villon l, Cristol JP, et al. 
Activation of oxidative stress by acute glucose fluctuations 
compared with sustained chronic hyperglycemia in patients 
with type 2 diabetes. JAMA. 2006;295:1681-7. Medline:16609090 
doi:10.1001/jama.295.14.1681
2 de M bandeira s, da Fonseca lJ, da s Guedes G, rabelo lA, Goulart 
MO, Vasconcelos sM. Oxidative stress as an underlying contributor 
in the development of chronic complications in diabetes mellitus. 
int J Mol sci. 2013;14:3265-84. Medline:23385234 doi:10.3390/
ijms14023265
3 Evans Jl, Goldfine iD, Maddux bA, Grodsky GM. Oxidative stress 
and stress-activated signaling pathways: a unifying hypothesis of 
type 2 diabetes. Endocr rev. 2002;23:599-622. Medline:12372842 
doi:10.1210/er.2001-0039
4 Wohaieb sA, Godin DV. Alterations in free radical tissue-defense 
mechanisms in streptozocin-induced diabetes in rat. Effects of 
insulin treatment. Diabetes. 1987;36:1014-8. Medline:3301471 
doi:10.2337/diab.36.9.1014
5 McGuire DK, Winterfield Jr, rytlewski JA, Ferrannini E. blocking 
the renin-angiotensin-aldosterone system to prevent diabetes 
mellitus. Diab Vasc Dis res. 2008;5:59-66. Medline:18398815 
doi:10.3132/dvdr.2008.011
6 Andraws r, brown Dl. Effect of inhibition of the renin-angiotensin 
system on development of type 2 diabetes mellitus (meta-
analysis of randomized trials). Am J Cardiol. 2007;99:1006-12. 
Medline:17398202 doi:10.1016/j.amjcard.2006.10.068
7 Funakawa s, Okahara t, imanishi M, Komoro t, Yamamoto K, 
tochio Y. renin-angiotensin system and prostacyclin biosynthesis 
in streptozotocin diabetic rats. Eur J Pharmacol. 1983;94:27-33. 
Medline:6360695 doi:10.1016/0014-2999(83)90438-7
8 lieberman J, sastre A. serum angiotensin-converting enzyme: 
Elevation in diabetes mellitus. Ann intern Med. 1980;93:825-6. 
Medline:6255846 doi:10.7326/0003-4819-93-6-825
9 Abuissa H, Jones PG, Marso sP, O’Keefe JJH. Angiotensin-
converting enzyme inhibitors or angiotensin receptor blockers 
for prevention of type 2 diabetes: a meta-analysis of randomized 
clinical trials. J Am Coll Cardiol. 2005;46:821-6. Medline:16139131 
doi:10.1016/j.jacc.2005.05.051
10 Münzel t, Keaney JF Jr. Are ACE inhibitors a “magic bullet” against 
oxidative stress? Circulation. 2001;104:1571-4. Medline:11571254 
doi:10.1161/hc3801.095585
11 Hornig b, Kohler C, Drexler H. role of bradykinin in mediating 
vascular effects of angiotensin-converting enzyme inhibitors 
in humans. Circulation. 1997;95:1115-8. Medline:9054837 
doi:10.1161/01.Cir.95.5.1115
12 Couture r, Girolami JP. Putative roles of kinin receptors in 
the therapeutic effects of angiotensin 1-converting enzyme 
inhibitors in diabetes mellitus. Eur J Pharmacol. 2004;500:467-85. 
Medline:15464053 doi:10.1016/j.ejphar.2004.07.045
13 Ni A, Chao l, Chao J. transcription factor nuclear factor kappab 
regulates the inducible expression of the human b1 receptor gene 
in inflammation. J biol Chem. 1998;273:2784-91. Medline:9446586 
doi:10.1074/jbc.273.5.2784
14 Dias JP, talbot s, sénécal J, Carayon P, Couture r. Kinin b1 receptor 
enhances the oxidative stress in a rat model of insulin resistance: 
outcome in hypertension, allodynia and metabolic complications. 
Plos ONE. 2010;5:e12622. Medline:20830306 doi:10.1371/journal.
pone.0012622
15 Erdös EG, tan F, skidgel rA. Angiotensin i-converting enzyme 
inhibitors are allosteric enhancers of kinin b1 and b2 receptor 
function. Hypertension. 2010;55:214-20. Medline:20065150 
doi:10.1161/HYPErtENsiONAHA.109.144600
16 Chopra M, beswick H, Clapperton M, Dargie HJ, smith WE, 
McMurray J. Atioxidant effects of angiotensin-converting 
enzyme (ACE) inhibitors: free radical and oxidant scavenging 
are sulfhydryl dependent, but lipid peroxidation is inhibited by 
both sulfhydryl- and nonsulfhydryl-containing ACE inhibitors. 
J Cardiovasc Pharmacol. 1992;19:330-40. Medline:1378110 
doi:10.1097/00005344-199203000-00005
17 Evangelista s, Manzini s. Antioxidant and cardioprotective 
properties of the sulphydryl angiotensin-converting 
enzyme inhibitor zofenopril. J int Med res. 2005;33:42-54. 
Medline:15651714 doi:10.1177/147323000503300103
18 Chin bs, langford NJ, Nuttall sl, Gibbs Cr, blann AD, lip GY. 
Anti-oxidative properties of beta-blockers and angiotensin-
converting enzyme inhibitors in congestive heart failure. Eur J 
379Mikrut et al: ACE inhibition, bradykinin receptors blockade, and oxidative status in hyperglycemia
www.cmj.hr
Heart Fail. 2003;5:171-4. Medline:12644008 doi:10.1016/s1388-
9842(02)00251-9
19 Manolis AJ, Marketou ME, Gavras i, Gavras H. Cardioprotective 
properties of bradykinin: role of the b(2) receptor. Hypertens res. 
2010;33:772-7. Medline:20505673 doi:10.1038/hr.2010.82
20 Oeseburg H, iusuf D, van der Harst P, van Gilst WH, Henning rH, 
roks AJ. bradykinin protects against oxidative stress-induced 
endothelial cell senescence. Hypertension. 2009;53:417-22. 
Medline:19075096 doi:10.1161/HYPErtENsiONAHA.108.123729
21 bell rH Jr, Hye rJ. Animal models of diabetes mellitus: physiology 
and pathology. J surg res. 1983;35:433-60. Medline:6314046 
doi:10.1016/0022-4804(83)90034-3
22 Kopecky rt, thomas FD, McAfee JG. Furosemide augments the 
effects of captopril on nuclear studies in renovascular stenosis. 
Hypertension. 1987;10:181-8. Medline:3301665 doi:10.1161/01.
HYP.10.2.181
23 Madeddu P, Anania V, Parpaglia PP, Demontis MP, Varoni MV, Pisanu 
G, et al. Effects of Hoe 140, a bradykinin b2-receptor antagonist, 
on renal function in conscious normotensive rats. br J Pharmacol. 
1992;106:380-6. Medline:1327379 doi:10.1111/j.1476-5381.1992.
tb14344.x
24 Zuccollo A, Navarro M, Catanzaro O. Effects of b1 and b2 kinin 
receptor antagonists in diabetic mice. Can J Physiol Pharmacol. 
1996;74:586-9. Medline:8884024 doi:10.1139/y96-047
25 D’souza rs, bhounsule sA, Dhume VG. Comparison of the effects 
of captopril and enalapril on oxyphenbutazone and ethanol-
induced gastric lesions in rats. indian J Physiol Pharmacol. 
1990;34:206-8. Medline:2286425
26 Frew JE, Jones P, scholes G. spectrophotometric determination 
of hydrogen peroxide and organic hydropheroxides at low 
concentrations in aqueous solution. Anal Chim Acta. 1983;155:139-
50. doi:10.1016/s0003-2670(00)85587-7
27 Vanhoutte PM, boulanger CM, illiano sC, Nagao t, Vidal M, 
Mombouli JV. Endothelium-dependent effects of converting-
enzyme inhibitors. J Cardiovasc Pharmacol. 1993;22 suppl 5:s10-6. 
Medline:7508046 doi:10.1097/00005344-199322005-00003
28 scheen AJ. Prevention of type 2 diabetes mellitus through 
inhibition of the renin-angiotensin system. Drugs. 2004;64:2537-
65. Medline:15516153 doi:10.2165/00003495-200464220-00004
29 Eshaq rs, Wright Ws, Harris Nr. Oxygen delivery, consumption, 
and conversion to reactive oxygen species in experimental 
models of diabetic retinopathy. redox biol. 2014;2:661-6. 
Medline:24936440 doi:10.1016/j.redox.2014.04.006
30 buléon M, Allard J, Jaafar A, Praddaude F, Dickson Z, ranera Mt, et 
al. Pharmacological blockade of b2-kinin receptor reduces renal 
protective effect of angiotensin-converting enzyme inhibition in 
db/db mice model. Am J Physiol renal Physiol. 2008;294:F1249-56. 
Medline:18367657 doi:10.1152/ajprenal.00501.2007
31 Kakoki M, Kizer CM, Yi X, takahashi N, Kim Hs, bagnell Cr, et al. 
senescence-associated phenotypes in Akita diabetic mice are 
enhanced by absence of bradykinin b2 receptors. J Clin invest. 
2006;116:1302-9. Medline:16604193 doi:10.1172/JCi26958
32 Westermann D, Walther t, savvatis K, Escher F, sobirey M, riad 
A, et al. Gene deletion of the kinin receptor b1 attenuates 
cardiac inflammation and fibrosis during the development of 
experimental diabetic cardiomyopathy. Diabetes. 2009;58:1373-81. 
Medline:19276445 doi:10.2337/db08-0329
33 Mastan rao Y, Aparna lakshmi i, saroja M. Effect of ACE inhibitors 
on antioxidant status in streptozotocin induced diabetic rats. Asian 
J Pharm Clin res. 2011;4:134-7.
34 tasdemir s, Parlakpinar H, Acet A. role of bradykinin in the 
cardioprotective effects of captopril and angiotensin ii receptor 
blockers (At1, At2) on myocardial ischemia-reperfusion injury in 
rats. Health Med. 2013;7:1274-80.
35 Guang C, Phillips rD, Jiang b, Milani F. three key proteases–
angiotensin-i-converting enzyme (ACE), ACE2 and renin–within 
and beyond the renin-angiotensin system. Arch Cardiovasc 
Dis. 2012;105:373-85. Medline:22800722 doi:10.1016/j.
acvd.2012.02.010
36 Wysocki J, Ortiz-Melo Di, Mattocks NK, Xu K, Prescott J, Evora K, et 
al. ACE2 deficiency increases NADPH-mediated oxidative stress 
in the kidney. Physiol rep. 2014;2:e00264. Medline:24760518 
doi:10.1002/phy2.264
37 song b, Jin H, Yu X, Zhang Z, Yu H, Ye J, et al. Angiotensin-
converting enzyme 2 attenuates oxidative stress and VsMC 
proliferation via the JAK2/stAt3/sOCs3 and profilin-1/MAPK 
signaling pathways. regul Pept. 2013;185:44-51. Medline:23816468 
doi:10.1016/j.regpep.2013.06.007
38  tipnis sr, Hooper NM, Hyde r, Karran E, Christie G, turner AJ. A 
human homolog of angiotensin-converting enzyme: cloning and 
functional expression as a captopril-insensitive carboxypeptidase. 
J biol Chem. 2000;275:33238-43. Medline:10924499 doi:10.1074/
jbc.M002615200
39 Malfitano C, De Angelis K, Fernandes t, Wichi rb, rosa K, 
Pazzine M, et al. low-dose enalapril reduces angiotensin ii and 
attenuates diabetic-induced cardiac and autonomic dysfunctions. 
J Cardiovasc Pharmacol. 2012;59:58-65. Medline:21921804 
doi:10.1097/FJC.0b013e3182354776
40 lavrentyev EN, Malik Ku. High glucose-induced Nox1-derived 
superoxides downregulate PKC-βii, which subsequently decreases 
ACE2 expression and ANG(1-7) formation in rat VsMCs. Am J 
Physiol Heart Circ Physiol. 2009;296:H106-18. Medline:18978194 
doi:10.1152/ajpheart.00239.2008
41 lavrentyev EN, Malik Ku. High glucose (HG)-induced 
angiotensin-converting enzyme 2 (ACE2) and angiotensin (1–7) 
[Ang (1–7)] decrease is prevented by captopril, losartan and 
insulin in rat vascular smooth muscle cells (VsMCs). FAsEb J. 
2008;22(suppl):912.18. 
42 Frantz ED, Crespo-Mascarenhas C, barreto-Vianna Ar, Aguila Mb, 
Mandarim-de-lacerda CA. renin-angiotensin system blockers 
BASIC SCIENCE380 Croat Med J. 2016;57:371-80
www.cmj.hr
protect pancreatic islets against diet-induced obesity and insulin 
resistance in mice. Plos ONE. 2013;8:e67192. Medline:23894285 
doi:10.1371/journal.pone.0067192
43 santos rA, Ferreira AJ, simőes E, silva AC. recent advances in 
the angiotensin-converting enzyme 2-angiotensin(1-7)-Mas axis. 
Exp Physiol. 2008;93:519-27. Medline:18310257 doi:10.1113/
expphysiol.2008.042002
44 Echeverría-rodríguez O, Del Valle-Mondragón l, Hong E. 
Angiotensin 1-7 improves insulin sensitivity by increasing 
skeletal muscle glucose uptake in vivo. Peptides. 2014;51:26-30. 
Medline:24184594 doi:10.1016/j.peptides.2013.10.022
45 liu C, lv XH, li HX, Cao X, Zhang F, Wang l, et al. Angiotensin-
(1-7) suppresses oxidative stress and improves glucose uptake 
via Mas receptor in adipocytes. Acta Diabetol. 2012;49:291-9. 
Medline:22042130 doi:10.1007/s00592-011-0348-z
46 Zhang K, Meng X, li D, Yang J, Kong J, Hao P, et al. Angiotensin(1-7) 
attenuates the progression of streptozotocin-induced diabetic 
renal injury better than angiotensin receptor blockade. Kidney int. 
2015;87:359-69. Medline:25075768 doi:10.1038/ki.2014.274
47 Förstermann u, Münzel t. Endothelial nitric oxide synthase 
in vascular disease. From marvel to menace. Circulation. 
2006;113:1708-14. Medline:16585403 doi:10.1161/
CirCulAtiONAHA.105.602532
48 Oak JH, Cai H. Attenuation of angiotensin ii signaling recouples 
eNOs and inhibits nonendothelial NOX activity in diabetic mice. 
Diabetes. 2007;56:118-26. Medline:17192473 doi:10.2337/db06-
0288
49 tabbi-Anneni i, buchanan J, Cooksey rC, Abel ED. Captopril 
normalizes insulin signaling and insulin-regulated substrate 
metabolism in obese (ob/ob) mouse hearts. Endocrinology. 
2008;149:4043-50. Medline:18450963 doi:10.1210/en.2007-1646
50 Yamazaki t, tanimoto M, Gohda t, Ohara i, Hagiwara s, 
Murakoshi M, et al. Combination effects of enalapril and 
losartan on lipid peroxidation in the kidneys of KK-Ay/ta mice. 
Nephron Exp Nephrol. 2009;113:e66-76. Medline:19609084 
doi:10.1159/000228714
51 de Cavanagh EM, inserra F, Ferder l, Fraga CG. Enalapril and 
captopril enhance glutathione-dependent antioxidant defenses 
in mouse tissues. Am J Physiol regul integr Comp Physiol. 
2000;278:r572-7. Medline:10712274
52 Kudoh A, Matsuki A. Effects of angiotensin-converting enzyme 
inhibitors on glucose uptake. Hypertension. 2000;36:239-44. 
Medline:10948084 doi:10.1161/01.HYP.36.2.239
53 santos sH, braga JF, Mario EG, Pôrto lC, rodrigues-Machado 
Mda G, Murari A, et al. improved lipid and glucose metabolism 
in transgenic rats with increased circulating angiotensin-(1-7). 
Arterioscler thromb Vasc biol. 2010;30:953-61. Medline:20203301 
doi:10.1161/AtVbAHA.109.200493
54 Prasannarong M, santos Fr, Henriksen EJ. ANG-(1-7) reduces ANG 
ii-induced insulin resistance by enhancing Akt phosphorylation 
via a Mas receptor-dependent mechanism in rat skeletal 
muscle. biochem biophys res Commun. 2012;426:369-73. 
Medline:22960175 doi:10.1016/j.bbrc.2012.08.093
55 Giani JF, Gironacci MM, Muńoz MC, Peńa C, turyn D, Dominici FP. 
Angiotensin-(1–7) stimulates the phosphorylation of JAK2, irs-1 
and Akt in rat heart in vivo: role of the At1 and Mas receptors. Am 
J Physiol Heart Circ Physiol. 2007;293:H1154-63. Medline:17496209 
doi:10.1152/ajpheart.01395.2006
56 Katayama s, inaba M, Maruno Y, Morita t, Awata t, Oka Y. Glucose 
intolerance in spontaneously hypertensive and Wistar-Kyoto 
rats: enhanced gene expression and synthesis of skeletal 
muscle glucose transporter 4. Hypertens res. 1997;20:279-86. 
Medline:9453263 doi:10.1291/hypres.20.279
57 Wakisaka M, Yoshinari M, Nakamura s, Asano t, sonoki K, shi AH, et 
al. suppression of sodium-dependent glucose uptake by captopril 
improves high glucose-induced morphological and functional 
changes of cultured bovine retinal pericytes. Microvasc res. 
1999;58:215-23. Medline:10527765 doi:10.1006/mvre.1999.2178
58 de Cavanagh EM, insera F, Ferder l, romano l, Ercole l, Fraga 
CG. superoxide dismutase and glutathione peroxidase activities 
are increased by enalapril and captopril in mouse liver. FEbs 
lett. 1995;361:22-4. Medline:7890034 doi:10.1016/0014-
5793(95)00137-X
59 Petrov l, Atanassova M, Alexandrova A. Comparative study of the 
antioxidant activity of some thiol-containing substances. Cent Eur 
J Med. 2012;7:269-73.
60 Chopra M, scott N, McMurray J, Mclay J, bridges A, smith WE, 
et al. Captopril: a free radical scavenger. br J Clin Pharmacol. 
1989;27:396-9. Medline:2655686 doi:10.1111/j.1365-2125.1989.
tb05384.x
61 Danser AHJ. renin-angiotensin system – plasma versus tissues. 
in: unger t, schökens bA, editors. Angiotensin Vol.1. berlin 
Heidelberg: springer-Verlag;2004. p.129-148. Medline: 
62 singh VP, le b, Khode r, baker KM, Kumar r. intracellular 
angiotensin ii production in diabetic rats is correlated with 
cardiomiocyte apoptosis, oxidative stress, and cardiac fibrosis. 
Diabetes. 2008;57(12):3297-306. Medline:18829990 doi:10.2337/
db08-0805
